Alexandra Balshi, John P Dempsey, Nova Manning, Grace Leuenberger, Ursela Baber, Jacob A Sloane
{"title":"恶性黑色素瘤和多发性硬化症治疗：FDA不良事件报告系统的歧化分析。","authors":"Alexandra Balshi, John P Dempsey, Nova Manning, Grace Leuenberger, Ursela Baber, Jacob A Sloane","doi":"10.1177/13524585251342725","DOIUrl":null,"url":null,"abstract":"<p><p>Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2.30; 95% confidence interval, 2.16-2.45; χ<sup>2</sup>, 702.33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"13524585251342725"},"PeriodicalIF":5.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.\",\"authors\":\"Alexandra Balshi, John P Dempsey, Nova Manning, Grace Leuenberger, Ursela Baber, Jacob A Sloane\",\"doi\":\"10.1177/13524585251342725\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2.30; 95% confidence interval, 2.16-2.45; χ<sup>2</sup>, 702.33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations.</p>\",\"PeriodicalId\":520714,\"journal\":{\"name\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"volume\":\" \",\"pages\":\"13524585251342725\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585251342725\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis (Houndmills, Basingstoke, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/13524585251342725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.
Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2.30; 95% confidence interval, 2.16-2.45; χ2, 702.33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
